Panacea Biotec Valuation

Is PANACEABIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PANACEABIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PANACEABIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PANACEABIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PANACEABIO?

Key metric: As PANACEABIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PANACEABIO. This is calculated by dividing PANACEABIO's market cap by their current revenue.
What is PANACEABIO's PS Ratio?
PS Ratio	4.7x
Sales	₹5.50b
Market Cap	₹25.11b

PANACEABIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.3x
Enterprise Value/EBITDA	1108.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PANACEABIO's PS Ratio compare to its peers?

The above table shows the PS ratio for PANACEABIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.6x
524669 Hester Biosciences	6.4x	n/a	₹20.2b
532039 Zenotech Laboratories	13x	n/a	₹4.7b
NIRMAN Nirman Agri Genetics	1.6x	n/a	₹2.4b
524663 Bharat Immunologicals & Biologicals	13.3x	n/a	₹1.0b
PANACEABIO Panacea Biotec	4.7x	n/a	₹25.1b

Price-To-Sales vs Peers: PANACEABIO is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (8.7x).

Price to Sales Ratio vs Industry

How does PANACEABIO's PS Ratio compare vs other companies in the Asian Biotechs Industry?

72 Companies	Price / Sales	Estimated Growth	Market Cap

72 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PANACEABIO is good value based on its Price-To-Sales Ratio (4.7x) compared to the Asian Biotechs industry average (9x).

Price to Sales Ratio vs Fair Ratio

What is PANACEABIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PANACEABIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PANACEABIO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹149.4b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,963.75

-1.3%

59.7%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹139.4b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,054.05

-2.0%

-24.6%